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Summary  
CD4+ T cell differentiation into multiple T helper  cell (Th) lineages is critical for optimal adaptive immune 
responses. This report identifies an intrinsic mechanism by which programmed death-1 receptor (PD-1) 
signaling imparted regulatory phenotype to Foxp3+ Th1 cells (denoted as Tbet+iTregPDL1 cells) and inducible 
regulatory T cells (iTregs). Tbet+iTregPDL1 cells prevented inflammation in murine models of experimental 
colitis and experimental graft versus host disease (GvHD). Programmed death ligand-1 (PDL-1) binding to 
PD-1 imparted regulatory function to Tbet+iTregPDL1 cells and iTreg cells by specifically down regulating 
endo-lysosomal protease asparaginyl endopeptidase (AEP). AEP regulated Foxp3 stability and blocking 
AEP imparted regulatory function in Tbet+iTreg cells. Also, Aep-/- iTreg cells significantly inhibited GvHD 
and maintained Foxp3 expression. PD-1 mediated Foxp3 maintenance in Tbet+ Th1 cells occurred both in 
tumor infiltrating lymphocytes (TIL) and during chronic viral infection. Collectively, this report has 
identified an intrinsic function for PD-1 in maintaining Foxp3 through proteolytic pathway.  
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Introduction 
Functional plasticity of cells belonging to the innate and adaptive immune system is necessary for 
the generation of robust immune responses while minimizing detrimental effects towards the host. CD4+ T 
cell plasticity has been extensively studied in recent years (O'Shea and Paul, 2010). A plasticity index has 
been proposed for the various T helper cell lineage subsets: with each subset possessing different lineage 
flexibility (Murphy and Stockinger, 2010).  Of the numerous CD4+ T cell subsets, peripherally generated 
T regulatory (Tregs) cells and T helper (Th) 17 cells are regarded as plastic (Bailey-Bucktrout et al., 2013; 
Boniface et al., 2010; Gagliani et al., 2015; McGeachy et al., 2007; Mukasa et al., 2010; Yang et al., 2008) 
whereas functional stability has been attributed towards thymic derived Treg cells (tTregs) (Miyao et al., 
2012), Th1 and Th2 cell lineages. Both Th2 cells (Adeeku et al., 2008; Hegazy et al., 2010; Peine et al., 
2013; Taylor et al., 2006) and tTreg cells (Feng et al., 2014; Laurence et al., 2012; Zhou et al., 2009) have 
been demonstrated to be plastic in disease conditions. In light of these studies Th1 cells remain the lineage 
with the least evidence of functional flexibility. Furthermore, the molecular mechanisms that influence 
lineage stability in Th1 cells are poorly defined (Brown et al., 2015). 
In contrast to work on cytokine signaling (O'Shea and Paul, 2010), the role of co-receptors in 
mediating functional plasticity has received minimal attention. One such co-inhibitory molecule that has 
been implicated in Th cell plasticity is programmed death ligand-1 (PDL-1 or B7-H1). In our previous 
work, we have found that PDL-1 can induce Foxp3 in human Th1 cells (Amarnath et al., 2011), consistent 
with work in murine naïve T cells (Francisco et al., 2009). In the tumor microenvironment, PDL-1 
expression coincides with increased intra-tumor Foxp3+ T cells (Duraiswamy et al., 2013; Jacobs et al., 
2009) suggesting that PDL-1 may play a role in maintaining Foxp3 expression in CD4+ Th subsets. PDL-1 
binds to its receptor PD-1 on T cells which signals through the inhibitory phosphatase SHP1 (Chemnitz et 
al., 2004). SHP1 or SHP2 recruitment results in STAT de-phosphorylation (Amarnath et al., 2011) (Taylor 
et al., 2017), potentially destabilizing the transcriptional signature of Th1 cell lineage. 
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In the current study, we have elucidated an intrinsic mechanism by which PD-1 signaling maintains 
Foxp3 in Tbet+iTreg and iTreg cells. The data presented here demonstrates that PD-1 can inhibit a functional 
nuclear pool of active asparaginyl endopeptidase (AEP), an endo-lysosomal protease previously implicated 
in antigen processing in dendritic cells (Dall and Brandstetter, 2016; Manoury et al., 1998; Manoury et al., 
2002). We show that AEP is responsible for destabilizing Foxp3 in both iTregs and Tbet+iTreg cells. We 
found that PD-1 activation significantly enhanced Foxp3 expression in primed anti-viral and anti-tumor 
Tbet+Th1 cells, which was reversed in the presence of a blocking antibody to PDL-1. Of note, PDL-1 
blockade did not reverse Tbet+Th1 cell conversion and iTreg cell induction in the absence of AEP. 
Therefore, this study demonstrates that downregulation of AEP is necessary for PD-1 generated Foxp3 
stability. 
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Results 
PD-1 signaling, in the absence of TGF-1, reinforces Foxp3 expression in CD4+Tbet+Foxp3- T cells  
To investigate if PD-1 maintains Foxp3 in Th1 cells, previously described Tbx21ZsGreen reporter 
mice were crossed with Foxp3RFP mice. Flow sorted CD4+Tbet+Foxp3-T cells (Figures 1A and 1B, S1A 
and S1B) were differentiated under iTreg cell conditions (Tbet+iTreg cells) or iTreg cell conditions with 
PDL-1 (Tbet+iTregPDL1 cells) (Figures 1A-1D). When subsets were maintained with interleukin-2 (IL-2) 
and transforming growth factor- (TGF-, Foxp3 expression under both culture conditions was similar 
(Figure 1D). In culture conditions where TGF-1 was omitted from day 4 until day 7 (Figure 1E), a 
significant loss in Foxp3 was noted within the Tbet+iTreg cells compared with Tbet+iTregPDL1 cells (Figures 
1F and 1G). We next purified Foxp3+ cells from both groups (denoted hereafter as Tbet+iTreg cells and 
Tbet+ iTregPDL1 cells) and examined their function in vitro. Both populations suppressed effector T cell 
proliferation in vitro to a similar extent (Figures S1C-S1E). Tbet+iTregPDL1 cells secreted less IL-10 and 
IFN- when compared to Tbet+Foxp3- cells (Figure S1F). These results indicate that PDL1 signaling 
maintains Foxp3 expression in Tbet+iTreg cells in the absence of TGF- 
 
PDL1 induces stable regulatory phenotype in Tbet+iTregPDL1 cells during experimental autoimmune colitis 
and graft vs host disease (GvHD)   
The in vivo regulatory potential of Tbet+iTreg cells and Tbet+iTregPDL1 cells was next evaluated. 
Rag2-/- mice were reconstituted with CD4+CD45RBhiCD25- naïve T effector cells alone (CD45.1+) or in 
conjunction with various indicated flow sorted iTreg cell populations (CD45.2+). Cohorts that received 
either T effector cells alone or together with Tbet+iTreg cells succumbed to colitis. By contrast, animals 
that received effector T cells and Tbet+iTregPDL1 cells were protected from clinical weight loss (Figure 
S2A). We next evaluated T effector cell function in the spleen and lamina propria lymphocytes (LPL). 
Adoptive transfer of Tbet+iTregPDL1 cells significantly diminished interferon - (IFN-γ) production in the T 
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effectors in the spleen (Figures 2A and 2B) and in the LPL (Figure S2B). These results suggested that 
despite both groups of Th1 cells expressing Foxp3, only Tbet+iTregPDL1 cells had a robust regulatory 
phenotype in vivo that was comparable to iTreg cells generated from naïve CD4+ cells. We next investigated 
if the ability of Tbet+iTregPDL1 cells to prevent colitis was attributed to Foxp3 stability in these cells. Foxp3 
expression was measured within the CD45.2+ cells isolated from the spleen (Figures 2C and 2D) and 
lamina propria (Figure S2C) at day 60 post adoptive transfer. Frequency of Foxp3 expressing 
Tbet+iTregPDL1 cells was increased when compared to cohorts that received Tbet+iTreg cells. Finally, we 
evaluated the inherent capacity of these cells to revert back to IFN- producers. We found that the capacity 
of Tbet+iTregPDL1 cells to secrete IFN- was significantly diminished when compared to Tbet+iTreg cells 
(Figure 2E).  
The potency of Tbet+iTregPDL1 cells was then tested in an allogeneic murine GvHD model. We 
found that BALB/c host mice that received B6 cells stimulated under iTreg cells plus PDL-1 conditions 
had higher survival rates, diminished weight loss and histological manifestations compared with mice that 
received cells stimulated under iTreg cell conditions alone, reaching significance in cohorts with 
Tbet+iTregPDL1 cells (Figures 2F, S2D and S2E). We next measured Foxp3 expression within the CD45.2+ 
iTreg, iTregPDL1, Tbet+iTreg and Tbet+iTregPDL1 cells at day 14 post-transplant and found significant Foxp3 
expression was maintained within Tbet+iTregPDL1 cells (Figure 2G). We next evaluated the amount of 
alloreactive IFN-γ expression in the cohorts that received Tbet+ iTreg and Tbet+ iTregPDL1 cells. A significant 
reduction in the Tbet+iTregPDL1 cell treated cohorts (Figure 2H) was noted. These data indicate that PDL-1 
induced a stable regulatory phenotype in Tbet+ iTregPDL1 cells. 
 
PD-1 signaling downregulates asparaginyl endopeptidase in Tbet+ iTregPDL1 and iTregPDL1 cells 
In order to identify PD-1 dependent molecular mechanism that was operational in Tbet+iTregPDL1 
cells, we first evaluated AKT and mTOR signaling pathway as previously reported in iTreg cells (Francisco 
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et al., 2009). No difference in the phosphorylation of AKT or mTOR pathway was observed (Figure S3A). 
Therefore, we next evaluated the gene expression profile of Tbet+iTreg and Tbet+iTregPDL1 cells. We found 
downregulation of a protease namely asparaginyl endopeptidase (AEP) in Tbet+iTregPDL1 cells using micro-
array analysis (Figure S3B). Consistent with our microarray data, AEP protein expression (Figure 3A) and 
enzyme activity was significantly decreased in Tbet+ iTregPDL1 cells compared with Tbet+ iTreg cells 
(Figures S3C and S3D). The active form of AEP was evaluated by using LE28 probe [which emits a 
fluorescent signal when ligated to the active form of AEP (Edgington et al., 2013); Figure S3C]. We next 
evaluated if a functional nuclear pool of AEP was available within Tbet+iTreg cells, as previously reported 
(Dall and Brandstetter, 2016; Haugen et al., 2013; Kosugi et al., 2009), using LE28 by imaging flow 
cytometry. We found a significant increase in the presence of active nuclear AEP in Tbet+iTreg cells 
compared with Tbet+iTregPDL1 cells (Representative image Figures 3B and 3C; Summary of nuclear 
activity Figure S3E). In addition, active AEP was expressed in iTreg cells generated in the absence of 
PDL-1, but not in polarized Th1, Th2, CD4+CD25- or CD4+CD25+ T cells (Figures 3D and S3F). PDL-1 
treated iTreg cell cultures showed relatively diminished AEP activity, which was abrogated in Pd1-/- iTreg 
cells (Figures 3D and S3G). Finally, we evaluated the presence of nuclear AEP by immuno blotting and 
confocal microscopy. In all cases, we found AEP to be expressed within the nucleus in Tbet+iTregs and 
iTreg cells (Figures 3E and 3F), which was limited by the addition of PDL-1 (Figure 3F). 
Using confocal microscopy and imaging flow cytometry on cells stained with fluorescent markers 
for Foxp3 protein and active nuclear AEP, we found that Foxp3 and AEP were co-localized in Tbet+iTreg 
cells and iTreg cells (Figures 3G-3I and S3H-S3O). This result prompted us to examine whether Foxp3 
was a specific target of AEP or whether AEP indirectly regulated Foxp3 expression. Co-incubation of 
activated AEP with Foxp3 protein demonstrated that AEP directly cleaved Foxp3, but not T-bet protein 
(Figure 3J). In spite of possessing numerous asparaginyl sites, T-bet protein was refractory to AEP 
cleavage, whereas minimally cleaved Foxp3 bands (band 2 and 3) were noted by immuno blotting. 
However, band 3 was noted in conditions, which incorporated AEP inhibitor (Figures 3J). When we 
 9 
subjected band 2 and band 3 to high-throughput mass spectrometry, AEP specific peptide cleavage product 
was found in band 2 and not band 3. Data from this analysis identified a specific semi-tryptic cleaved 
peptide within band 2 which was a target for AEP [N155; AEP cleaves after Asn (N)]. No other AEP 
specific targets were identified within the two bands (Figure 3K and Table S1). 
We next evaluated Foxp3 protein turnover within Tbet+iTreg cells in the presence of AEP inhibitor. 
Significant inhibition of Foxp3 protein degradation was noted in the presence of AEP inhibitor in 
Tbet+iTreg cells (Figure S4A; top and bottom panel). To confirm this, we evaluated Foxp3 turnover in 
WT and Aep-/- iTreg cells; again, Foxp3 turnover was lower in Aep-/- iTreg cells as compared to WT iTreg 
cells (Figure S4B; top and bottom panels). 
To further investigate the direct action of AEP on Foxp3, we designed a human Foxp3 mutant 1 
(all N mutated to A (alanine); 12 sites; Figures S4C and S4D).  We tested if the AEP resistant mutant 
Foxp3 had enhanced stability in in vitro experiments. WT and mutant 1 were transduced into HEK293T 
cells and then rate of Foxp3 degradation in the presence of AEP and AEP inhibitor was evaluated. AEP 
specifically degraded WT Foxp3 protein while showing no activity on mutated Foxp3 mutant 1 protein 
(Figures S4E and S4F). These in vitro experiments suggest that AEP may directly act on Foxp3 protein 
within T cells. 
 
Deletion of AEP specific cleavage site in Foxp3 results in prevention of alloreactive GvHD 
We next evaluated the in vivo function of cells that were transduced with WT Foxp3 (mouse and 
human) or Foxp3 mutant 2 (human) and mouse Foxp3 mutant 1. For these experiments, we first constructed 
human WT and mutated Foxp3 (N154; Asn site is at 154 in human) as our mass spectrometry data were 
obtained from human Foxp3 protein. In addition, we also constructed WT and mutated (N153; Asn site is 
at 153 in mouse) mouse Foxp3. All the constructs were transduced into naïve mouse T cells and Foxp3 
expression was evaluated (Figure 4A), and nuclear localization (Figure S5A) for each construct were 
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verified at day 4 post-transduction. The transduced WT and mutant forms of Foxp3 were functional as they 
suppressed the capacity of the transduced cells to produce IFN-; IFN- being a specific target of Foxp3 in 
vitro (Figure S5B). The in vivo suppressive function of transduced T cells was tested in a murine GvHD 
model (Laurence et al., 2012). We found that T cells transduced with mutated versions of Foxp3 (both 
mouse and human) significantly prevented GvHD lethality in murine recipients as compared to WT Foxp3 
(Figure 4B). 
 
Inhibiting AEP activity maintains Foxp3 expression in Tbet+iTreg cells in vivo 
We next tested the role of AEP in limiting Foxp3 stability in Tbet+iTreg cells using an AEP specific 
inhibitor (AEPi). First, the in vitro efficacy of AEPi was tested in iTreg cell cultures. Naïve CD4+CD25- T 
cells from WT mice were expanded under iTreg cell conditions (experimental outline Figure 1E). Certain 
culture conditions were supplemented with AEPi. We found that the AEPi cultures had significantly higher 
Foxp3 expression as compared to the control cultures, whereas no significant difference was noted in Aep-
/- iTreg cell cultures, thus confirming the specificity of the AEP inhibitor (Figures S5C and S5D). Splenic 
Tbet+Foxp3- Th1 cells were expanded into Tbet+iTreg cells in the presence of AEP inhibitor (MV026630, 
100M) and then Foxp3 stability was tested in vivo. Murine recipients were reconstituted with CD4+CD25- 
naïve T cells (CD45.1+) along with Tbet+iTreg cells (CD45.2+) expanded in the presence of vehicle (DMSO) 
or AEP inhibitor (MV026630).  At day 14 post-transplant, the frequency of Foxp3+ cells within the 
adoptively transferred Tbet+iTreg cells was measured. Tbet+iTreg cells generated in the presence of AEPi 
exhibited an enhanced frequency of Foxp3+ cells as compared to control Tbet+iTreg cells (Figures 4C and 
4D). To further evaluate the role of AEP in Tbet+iTreg cell function, we over-expressed AEP in 
Tbet+iTregPDL1 cells using a retro-virus. AEP overexpression and nuclear localization was first confirmed 
(Figures S5E and S5F) in Tbet+iTregPDL1 cells. We then tested the function of overexpressed AEP by 
transducing Aep-/- iTreg cells with either empty vector (EV) or AEP RV. At day 7 post expansion, Aep-/- 
iTreg cells were capable of expressing Foxp3, which was completely abrogated when AEP was 
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overexpressed (Figure S5G). We then evaluated the clinical outcome of over-expressing AEP (in 
Tbet+iTregPDL1 cells) or inhibiting AEP (in Tbet+iTreg cells) in acute GvHD. BALB/c mice that received 
B6 Tbet+iTregPDL1 cells with forced expression of AEP had a significantly higher mortality compared with 
those that received control B6 Tbet+iTregPDL1 cells. Similarly, Tbet+iTreg cells expanded with AEP inhibitor 
showed similar regulatory function to that of Tbet+ iTregPDL1 cells in vivo (Figure 4E). To further confirm 
the role of AEP in Treg cell function in vivo, a retroviral small inhibitory RNA (RV-shRNA) for AEP was 
utilized. AEP silencing in Tbet+iTreg cells was effective (Figures S5H-S5J). Murine recipients 
reconstituted with Tbet+iTreg cells transduced with AEP RV-shRNA had a significant delay in the loss of 
Foxp3 (Figures 4F-4H). Ablating AEP had minimal effect on the expression of Tbet in Tbet+ iTreg cells 
(Figure 4I). Finally, we mutated the nuclear localization sequence in AEP (AEP NLS mutant) and then 
evaluated Foxp3 stability. We found that overexpressing AEP NLS mutant in Aep-/- iTreg cells maintained 
Foxp3 expression but this was not the case in cohorts that overexpressed AEP WT protein (Figures S5K-
S5M). 
 
AEP deficiency modulates in vivo Treg cell function by maintaining Foxp3 expression 
To further assess the role of AEP in Foxp3 regulation, we evaluated the efficacy of iTreg cells from 
Aep-/- mice in an experimental murine model of GvHD. First, we characterized the CD4+ T cell compartment 
within Aep-/- mice. WT and Aep-/- CD4+ T cells had a similar phenotype with respect to T cell frequency 
and activation, but Aep-/- mice had higher Treg cell frequency (Figures 5A-5F and S6A and S6B). By 
contrast, no significant difference was noted in the cytokine expression by CD4+ T cells from WT and Aep-
/- mice (Figure S6C). Next, in vitro expanded iTreg cells from WT and Aep-/- naïve CD4+ T cells (Figure 
S6D) were used tested in GvHD.  Aep-/- iTreg cells were significantly efficient at preventing GvHD 
compared to WT iTreg cells (Figure 5G). Of note, cohorts treated with Aep-/- iTreg cells (CD45.2+) had 
significantly higher numbers of Foxp3+ cells in the spleen and lymph nodes (Figures 5H and S6E and 
S6F) as compared to WT iTreg cell treated cohorts.  
 12 
In order to explore the relationship between PD-1 signaling and AEP activation within T cells, we 
tested the frequency of Treg cells in Aep-/- mice under disease conditions in the presence of PDL-1 blocking 
antibody. A syngeneic B16F10 melanoma tumor model was used whereby WT and Aep-/- mice were 
reconstituted with tumor cells and the cohorts were treated with either isotype or PDL-1 antibody. At day 
11, tumors were resected and the tumor infiltrating lymphocytes (TILs) were tested for the frequency of 
Foxp3+Treg cells and Tbet+Foxp3+Treg cells. We found that Aep-/- cohorts had a small but significant 
increase in Foxp3+ TILs as compared to WT cohorts (Figures 5I and 5J). In the presence of anti-PDL-1, 
we saw a decrease in Foxp3+ TILs in the tumors of WT cohorts but no change in the Aep-/- cohorts (Figures 
5I and 5J). When we gated on Tbet+ TILs, we found a similar pattern with an elevated proportion of Tbet+ 
TIL’s expressing Foxp3 in the Aep-/-  compared with WT mouse cohorts and the addition of anti-PDL1 
significantly inhibiting Foxp3 expression only in the WT cohorts (Figures 5K and 5L). Collectively, these 
in vivo experiments confirm our in vitro data and identified PD-1 as a regulator of Foxp3 through AEP. 
 
Tbet+ Th1 cells primed during acute and chronic viral infections upregulate Foxp3 ex vivo 
We next investigated if Th1 cells arising during viral infection can also be induced to express 
Foxp3. First, during acute LCMV infection, a significant percentage of Tbet+Foxp3+ cells was observed at 
day 14 post infection (Figures 6A and 6B and S7A) and second, Tbet+Foxp3- cells had a significant PD-1 
expression (Figures S7B and S7C). These virus primed CD4+Tbet+Foxp3- cells were sorted on day 14 
post-infection and cultured in vitro under iTreg cell conditions with or without PDL-1. In both cases, iTreg 
cell-polarizing cytokines could induce Foxp3 expression in Th1 cells and this was enhanced to a small but 
significant extent in the presence of PDL-1 (Figure 6C).  Similarly, during chronic LCMV infection, a 
substantial increase was noted in Tbet+Foxp3+ cells at day 14 post infection in vivo (Figures 6D and 6E 
and S7D) and again, Tbet+Foxp3- cells had a significant PD-1 expression (Figures S7E and S7F). These 
chronic LCMV virus primed CD4+Tbet+Foxp3- cells were sorted on day 14 post-infection and cultured in 
vitro under iTreg cell conditions with or without PDL-1. In both cases iTreg cell-polarizing cytokines could 
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induce Foxp3 expression in Th1 cells and this was enhanced by a small but significant extent in the presence 
of PDL-1 (Figures 6F and 6G). In order to confirm that PDL-1 is required for conversion of Tbet+ cells 
into Tbet+pTreg cells during chronic LCMV, we adoptively transferred flow sorted CD45.2+Tbet+Foxp3- 
cells into CD45.1+ hosts infected with chronic LCMV. Mice were treated with either isotype or anti-PDL1 
antibody. At day 10, frequency of converted Tbet+Foxp3+ in the spleen was measured (Figures 6H and 
6I). Anti-PDL-1 treatment significantly inhibited the conversion of Tbet+ cells into Foxp3+ cells and 
enhanced the proliferation of both total and GP33 specific CD45.1+ CD8+ T cells in vivo (Figures S7G-
S7M).  
 
Tbet+pTreg cells are increased in the TILs of mice bearing B16F10 melanoma tumor 
In order to identify the biological context during which Tbet+pTreg cells arise from Tbet+Th1 cells, 
an animal model of B16F10 melanoma, where PD-1 based therapies play an important role, was used. 
Adoptive transfer of Tbet+Th1 cells into murine recipients with established tumor was performed (Outline 
of Experimental Methodology, Figure 7A). The emergence of Tbet+pTreg cells was then evaluated in the 
spleen and within the TILs. A significant increase in Tbet+pTreg cells was noted within the TILs in the 
tumor microenvironment (Figures 7B and 7C). We next tested if PDL-1 contributed to the differentiation 
of Tbet+Th1 cells into Tbet+iTreg cells in the tumor microenvironment. Stimulation with PDL-1 
significantly enhanced Foxp3 expression in sorted Tbet+Th1 cells from tumor bearing mice in ex vivo 
cultures (Figures 7D and 7E). We subsequently tested in vivo Tbet+ cell conversion in our tumor model. 
Rag2-/- mice were reconstituted with tumor cells followed by adoptive transfer of sorted Tbet+Foxp3- cells. 
Cohorts were either treated with isotype control or anti-PDL1 and then TILs were evaluated for 
Tbet+Foxp3+ cells. The frequency of Tbet+pTreg cells was significantly increased in the isotype treated 
cohorts but not in the anti-PDL1 treated murine recipients (Figures 7F-7H). The experiment was repeated 
with Tbet+Foxp3- cells that were transduced with either control shRNA RV or AEP shRNA RV. Consistent 
with our experiments performed using Aep-/- mice, AEP silencing rendered Tbet+ cells refractory to PDL1 
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blockade and resulted in significant conversion towards Tbet+Foxp3+ cells within the tumor 
microenvironment (Figures 7I and7J). Finally, we evaluated conversion of CD45.2+Tbet+ cells in CD45.1+ 
hosts that were reconstituted with B16F10 melanoma tumor. Certain cohorts were treated with either 
isotype or anti-PDL1 antibody. In this experimental condition, we again found that Tbet+Foxp3-cells were 
capable of converting to Tbet+iTreg cells within the tumor microenvironment, which was efficiently 
blocked in the presence of PDL1 antibody (Figures 7K and 7L). In all these experiments, CCR4 expression 
on Tbet+Foxp3+ cells within the tumor microenvironment was minimal (data not shown). These results 
suggest that Tbet+ cell conversion can occur in vivo within the tumor microenvironment and PDL1 blockade 
reverses the conversion of Tbet+ cells into Tbet+Foxp3+ cells. However, anti-PDL-1 effect in blocking Tbet+ 
cell conversion to Tbet+Foxp3+ cells is abrogated in the absence of AEP.  
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Discussion 
The regulation of Foxp3 in Tregs and T helper cell subsets is an active area of investigation and 
may help in understanding dysregulation of the immune system in disease processes. In this report, we have 
identified a proteolytic regulation of Foxp3 protein in iTreg cells, Tbet+iTreg cells and pTbet+Treg cells. 
We demonstrated that (a) PD-1 signaling maintains Foxp3 protein stability through regulating AEP, (b) 
AEP directly cleaves Foxp3 and results in Foxp3 instability in iTreg cells and pTreg cells and (c) inhibiting 
AEP resulted in enhanced Treg cell function. These data elucidate a basic mechanism that is operational in 
Treg cells and paves a path to the development of translational approaches for developing Treg cell based 
cell therapies. 
The results outlined in this paper are in agreement with the existence of these Tbet+Foxp3+ T cells 
in vivo. However, reports on Tbet+Treg cells (Hall et al., 2012; Koch et al., 2012; Koch et al., 2009; Levine 
et al., 2017) propose that tTreg cells are the likely precursors of Tbet+Treg cells.  The data presented here 
extend these observations and clearly demonstrate that an alternate pathway is involved in the upregulation 
of Foxp3 expression by Tbet+Foxp3- T cells.  
In vivo cell tracing experiments performed in the long-term colitis model highlights a mechanism 
by which PDL-1 imparts regulatory function to Tbet+iTregPDL-1 cells. During colitis Tbet+iTregPDL-1 cells 
had sustained Foxp3 expression after 60 days in an inflammatory environment unlike their counterpart 
Tbet+iTreg cells. These data support a regulatory mechanism whereby differentiation of Tbet+ cells in the 
presence of PDL-1 can result in sustained Foxp3 expression in vivo and led us to explore the molecular 
mechanisms by which PD-1 signaling regulated Foxp3 stability. We found a proteolytic pathway that was 
operational in maintaining Foxp3 protein stability in iTregs and Tbet+iTreg cells involving direct inhibition 
of the activity of AEP. PD-1 inhibition of AEP was independent of CD28 signaling (Hui et al., 2017; 
Kamphorst et al., 2017).  
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The notion that a specific protease can perform an essential specific proteolytic function is 
controversial as cells express many proteases that exhibit considerable functional redundancy (van Kasteren 
and Overkleeft, 2014). However, cell type specific differences in protease function have been previously 
reported. For example, AEP breaks down self-antigens in DCs (Manoury et al., 2002) and Cathepsin G 
performs this function in B cells (Burster et al., 2004). AEP activity has been reported both in lysosomes 
and in the nucleus of tumor cells (Haugen et al., 2013). Functionally AEP can induce tumor cell 
proliferation, migration and process antigens for optimal presentation by DCs (Andrade et al., 2011; Lin et 
al., 2014; Manoury et al., 1998).  In contrast to other lysosomal proteases, AEP is expressed in the cytosol 
and nucleus and the activity of AEP across both neutral and acidic pH has been previously reported (Haugen 
et al., 2013).  These observations enable a mechanism by which Foxp3 in the nucleus can be targeted by 
AEP.  
 The imaging and biochemical data presented here demonstrated that in T cells, AEP played a 
specific function in cleaving Foxp3, but not Tbet. These results are in accordance with previous AEP studies 
where it has been shown that AEP substrates in part are not amenable to other protease activity. In addition, 
AEP is well known for its substrate and cleavage specificity and often AEP mediated cleavage results in a 
functional immunological outcome in vivo (Manoury et al., 1998; Manoury et al., 2002). In T cells, AEP 
adheres to this phenotype, whereby it specifically targets and cleaves Foxp3 at a single site, which results 
in the instability of the protein. Therefore, our study implicates the occurrence of a proteolytic mediated 
regulation of Foxp3 in iTregs and Tbet+iTreg cells. 
The data presented here postulates a post-translational mechanism of Foxp3 protein regulation in 
addition to the previously described proteosomal pathway that is operational in Foxp3 regulation. However, 
deleting AEP was sufficient for maintaining Foxp3 protein in iTregs and Tbet+iTreg cells in vivo. In contrast 
to the proteosomal degradation study where an shRNA approach was used (Chen et al., 2013; van Loosdregt 
et al., 2013; Zhao et al., 2015), we have utilized a genetic loss of function model (Aep-/- mice) to demonstrate 
the stability of Foxp3 in vivo during acute inflammation. Furthermore, mutating AEP specific sites in Foxp3 
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protected mice from GvHD mediated lethality. Therefore, our data demonstrates that either AEP deficiency 
or Foxp3 mutated at AEP specific sites can enhance Treg cell function and is a primary pathway in 
modulating post-translational stability of Foxp3 protein. 
Our results suggest that AEP inhibitor can be used to generate large-scale Treg cells that are stable 
and are functionally robust in vivo. The use of PDL-1 to grow Tbet+iTreg cells may be efficacious but a 
substantial decrease in cell numbers can occur given the role of PD-1 in inhibiting T cell proliferation. 
Using AEP inhibitors, this hurdle can be overcome in order to generate large numbers of antigen primed 
Tbet+iTreg cells that maintain regulatory function in vivo. In addition, donor derived AEP deficient Treg 
cells can also be generated for the treatment of GvHD.  
Data from the acute and chronic LCMV infected mice further identified a role for PDL-1 in 
inducing Foxp3 in primed “antigen-specific” Tbet+ Th1 cells. Although insufficient cell numbers prevented 
us from isolating antigen specific T cells prior to ex vivo iTreg cell culture, the results presented here imply 
that PDL-1 can be used to generate iTreg cells from previously antigen primed Tbet+Th1 cells. Consistent 
with previous studies (Hall et al., 2012; Koch et al., 2012; Koch et al., 2009; Levine et al., 2017), we have 
also identified a unique population of Tbet+iTreg cells that expands in both acute and chronic LCMV. In 
summary, these experiments highlight many aspects of Tbet+iTreg cells: (a) primed CD44hiTbethiFoxp3+ 
cells can arise during acute and chronic LCMV infection, (b) primed CD4+CD44hiTbethiFoxp3- T cells can 
give rise to Tbet+Foxp3+ T cells in ex vivo cultures, and finally (c) blocking PDL-1 in vivo dampened 
Tbet+pTreg cell conversion, therefore confirming PDL1 as a critical mediator of Tbet+pTreg cell generation 
in chronic viral infection. 
In melanoma, Treg cell mediated tolerance has largely been attributed to the migration of Treg cells 
from the periphery to the tumor site (Spranger et al., 2013), while Tbet+Th1 cell conversion is largely 
unexplored. Since the microenvironment in melanoma provides an abundance of PDL-1 that can result in 
activation of PD-1 signaling on Tbet+ TILs, we explored and found that Tbet+Th1 cell conversion indeed 
occurred. However, this study does not address the contribution of hematopoietic versus non-hematopoietic 
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versus tumor tissue derived PDL-1 in inducing Treg cell conversion within the tumor microenvironment. 
The results presented here raise the possibility that the PDL-1 driven Treg cell generation within the TILs 
is dependent on AEP expression and that individuals who overexpress AEP within their Treg TIL 
populations may be more responsive to PD-1 and or PDL-1 based immunotherapeutics. 
In conclusion, this report has identified a mechanism by which sustained PD-1 signaling induces 
robust regulatory function in iTreg cells through post-translational regulation of the Foxp3 protein. 
Therefore, this study demonstrates an insightful interaction between co-inhibitory receptor signaling and 
protease activity and has elucidated the importance of these two signaling pathways in maintaining T 
regulatory phenotype.  
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Figure Legends 
Figure 1: Purified CD4+TbethiFoxp3- cells can upregulate Foxp3 under iTreg conditions 
Schematic representation of cell culture conditions under which sorted CD4+TbethiFoxp3- cells were 
expanded (A). Flow cytometry profile of Tbx21ZsGreen Foxp3RFP expressing CD4+ T helper cells (B), 
Foxp3 expression of CD4+TbethiFoxp3- cells in the presence of IL-2 and TGF- (Tbet+iTreg cells; C) or 
IL-2, TGF- and PDL-1 Fc chimera (Tbet+iTregPDL1 cells; C) post differentiation and expansion. Summary 
of %CD4+Foxp3+ cells expression in Tbet+iTreg cells  and Tbet+iTregPDL1 cells (D). Schematic 
representation of alternate cell culture conditions under which sorted CD4+TbethiFoxp3- cells were 
expanded (E). Foxp3 expression of CD4+TbethiFoxp3- cells in the presence of IL-2 (F), and summary of 
Foxp3 expression in different cell subsets (G). Experiments were repeated at least 5 times and each 
experiment was performed with n=5-9 mice. Cumulative data from all experiments are presented  
MeanSEM. Please also refer to Figure S1 
 
Figure 2: In vivo function of Tbet+iTreg cells and Tbet+iTregPDL1 cells 
Tbet+iTreg cells and Tbet+iTregPDL1 cells were generated and then utilized for the prevention of autoimmune 
colitis and alloimmune GvHD. B6.Rag2-/- mice were reconstituted with CD45.1+CD4+CD45RBhiCD25- T 
cells (4x105 cells/mouse) either alone or along with CD45.2+iTreg cells, iTreg PDL1 cells, Tbet+iTreg cells 
and Tbet+iTregPDL1 cells (1x105 cells/mouse) cells. At day 60 post adoptive transfer, spleens were 
characterized. Representative flow plots of intracellular IFN-γ and IL-10 cytokine expression in cohorts 
that either received CD4+ T effector cells alone, cohorts that received Tbet+iTreg cells in addition to T 
effector cells or cohorts that received Tbet+iTregPDL1 cells in addition to T effector cells (A). Summary of 
T cell effector cytokine IFN-γ in the various different cohorts within CD45.1+ cell populations (B). 
Representative flow plot of Foxp3 expression in CD45.2+CD4+Tbet+iTreg cells and Tbet+iTregPDL1 cells 
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(C), Summary of Foxp3 and IFN-expression in iTreg cells, iTregPDL1 cells, Tbet+iTreg cells and 
Tbet+iTregPDL1 cells (D-E). Function of Tbet+iTreg cells and Tbet+iTregPDL1 cells were assessed in an 
experimental model of GvHD. Survival curve of mice that succumbed to GvHD in the various different 
cohorts (F). Summary of Foxp3 expression in iTreg cells, iTregPDL1 cells, Tbet+iTreg cells and 
Tbet+iTregPDL1 cells on day 14 post-transplant (G). Alloreactive IFN-γ was measured using Luminex (H). 
Each experiment had n=3-5 mice per cohorts. Data shown is cumulative from 2 independent experiments. 
For survival curve, each cohort consisted of n=10 mice. Data are presented as MeanSEM. Please also refer 
to Figure S2. 
 
 
Figure 3: PDL-1 exposure downregulates asparaginyl endopeptidase in Tbet+iTreg cells 
Tbet+iTreg cells and Tbet+iTregPDL1 cell lysates were generated at pH 7 and were subjected to immuno 
blotting. Asparaginyl endopeptidase (AEP; Legumain; LGMN) was measured in the different subsets (A). 
Tbet+iTreg cells and Tbet+iTregPDL1 cells were differentiated and then stained with LE28 (measuring active 
AEP) along with LAMP1 and DAPI and then subjected to Amnis Imaging Cytometry. Representative 
images of active AEP enzyme expression in the nucleus in Tbet+iTreg cells (B) and Tbet+iTregPDL1 cells 
(C). AEP expression in iTreg cells, iTregPDL1 cells, Th1 cells, Th1PDL1 cells, Th2 cells and Th2PDL1 cells 
(D). AEP expression was determined in cytoplasmic and nuclear fractions of iTreg cells and Tbet+iTreg 
cells (E). iTreg cells, iTregPDL1 cells, Tbet+iTreg cells and Tbet+iTregPDL1 cells were stained with DAPI, 
Foxp3 PE and AEP cy5. Confocal microscopy showing AEP and Foxp3 expression inside the nucleus (F; 
red is AEP, green is Foxp3 and blue is DAPI). Foxp3 co-localization with AEP in the nucleus in Tbet+iTreg 
cells (G) and Tbet+iTregPDL1 cells was shown (H). Confocal microscopy detecting co-localization of AEP 
and Foxp3 within the nucleus in iTreg cells and Tbet+iTreg cells (I; white arrows show AEP co-association 
with Foxp3 within the nucleus). Tbet cleavage (J; left panel) and Foxp3 cleavage (J; right panel) in the 
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presence of AEP or AEP inhibitor. Spectral analysis of Foxp3 cleavage at N155 (K). Each experiment was 
repeated 3-5 times and representative data from one experiment is shown. Data are shown as MeanSEM. 
Please also refer to Figures S3 and S4. 
 
Figure 4: AEP specific Foxp3 mutants and AEP inhibition prevents GvHD 
Murine CD4+CD25- T cells were transduced with WT human Foxp3, Mutant (N154) human Foxp3, WT 
murine Foxp3 or mutant murine Foxp3 (N153). Transduction efficiency at day 4 was measured by flow 
cytometry (A). Host BALB/c mice were subjected to lethal total body irradiation (TBI; 950cGy) and then 
reconstituted with B6 T depleted bone marrow (BM, 5x106 cells) alone, or with CD4+CD25- T cells 
(CD45.1 marked, 0.1x106). Certain cohorts were treated with BM plus CD4+CD25- T plus non-transduced 
T cells (NT, 0.1x106) or T cells transduced with WT human Foxp3 (WT hFoxp3, 0.1x106), or human mutant 
Foxp3 (Mu hFoxp3, N154; 0.1x106) or murine WT Foxp3 (WT mFoxp3, 0.1x106) or murine mutant Foxp3 
(N153; Mu mFoxp3, 0.1x106). GvHD lethality was monitored (n=6 per cohort) (B). Host BALB/c mice 
were subjected to TBI and then reconstituted with bone marrow (BM, 107 cells), CD4+CD25- T effector 
cells (CD45.1 marked; 1x106 cells) and either Tbet+iTreg cells (1x106 cells) that were expanded with AEP 
inhibitor or control Tbet+iTreg cells (1x106 cells). At day 14 post-transplant, splenocytes were harvested 
and the Foxp3 was measured in the Tbet+iTreg cell populations (marked with CD45.2). Representative flow 
plots showing Foxp3 expression in the different cell populations (C); frequency of Foxp3 expression (D). 
A survival curve experiment was set up to test the efficacy of blocking AEP in preventing GvHD. Animals 
were conditioned with TBI and then reconstituted with BM alone or plus CD4+CD25- T cells. Cohorts were 
then treated with Tbet+iTreg cells, Tbet+iTreg cells expanded with AEP inhibitor (AEPi), Tbet+iTregPDL1 
cells or Tbet+iTregPDL1 cells overexpressing AEP (E). Experiments were repeated with CD45.2+ 
Tbet+iTregcells that were expanded with AEP shRNA or scramble shRNA and then tested in GvHD. 
Frequency and absolute numbers of CD45.2+Foxp3+ cells in the different cohorts (F-H) and absolute 
numbers of Tbet+ cells at day 14 post-transplant in Tbet+ iTreg cells (I). Experiments were repeated twice 
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with  n=4-6 mice for immunological studies and n=6-10 mice for survival curve. Representative data from 
one experiment is shown as MeanSEM. Please also refer to Figure S5. 
 
Figure 5: iTreg cells deficient in AEP inhibit GvHD and maintain Foxp3 expression in vivo 
Splenocytes from WT littermate controls and Aep-/- mice were characterized for CD4+ T cells, CD8+ T cells 
(A), T central and effector memory phenotype of CD4+ cells were characterized using CD62L and CD44 
markers (B). Cumulative data from n=4 mice on the frequency of CD4, CD8, CD44 and CD62L (C). Treg 
cell frequency was evaluated by intracellular Foxp3 expression (D). Cumulative data from n=5 mice of 
Foxp3 frequency (E), and Foxp3 mean fluorescence intensity (F). Host BALB/c mice were subjected to 
TBI and then reconstituted with B6 BM (107), CD4+CD25- T cells (CD45.1 marked; 0.1x106 cells) and 
either WT iTreg cells (0.1x106 cells) or Aep-/-iTreg cells (0.1x106 cells). Survival curve of cohorts that 
received the various cell populations (G). Foxp3+ cells in WT and Aep-/- iTreg cells (marked with CD45.2+) 
at day 14 post-transplant (H). WT and Aep-/- mice were reconstituted with 3x105 B16F10 melanoma cells 
subcutaneously and cohorts were treated with either isotype control or anti-PDL1 antibody at day 5, 7 and 
9. Mice were euthanized on day 11 and then evaluated for Foxp3+Treg cells and Tbet+Foxp3+Treg cells 
within the TILs. Representative flow plots of Treg cell frequency within the tumor (I), and summary of 
Treg cells in the various cohorts (J). TILs were gated on CD4+Tbet+ cells and then Foxp3 expression was 
evaluated. Representative flow plots of Tbet+Treg cell frequency within the tumor (K), and summary of 
Tbet+Treg cell in the various cohorts of TILs (L). Data are shown as MeanSEM, from one representative 
experiment. Each experiment was at least repeated twice and had n=5 mice for immunological studies or 
n=10 for survival. Please also refer to Figure S6. 
 
Figure 6: Virus primed CD4+Tbet+Foxp3- cells upregulate Foxp3 under iTreg and pTreg conditions  
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B6.Tbx21ZsgreenFoxp3RFP mice were infected with LCMV Armstrong (2x105 PFU) and then monitored 
for the presence of CD4+TbethiFoxp3+ cells. Representative flow plots from three individual experiments 
showing TbethiFoxp3+ cells in the CD4 compartment of murine recipients at various time points post 
infection (A). Summary of frequency of TbethiFoxp3+ T cells at various time points (B). Virus primed 
TbethiFoxp3- cells from acute LCMV infected mice were flow sorted at day 14 and then expanded under 
iTreg conditions in the absence or presence of PDL-1fc chimera. The frequency of Foxp3 expression in 
TbethiFoxp3- cell population in the absence or presence of PDL-1 after 7 days of ex vivo culture (C). 
B6.Tbx21ZsgreenFoxp3RFP mice were infected with LCMV clone 13 (2x106 PFU) and then monitored for 
the presence of CD4+TbethiFoxp3+ cells. Representative flow plots showing TbethiFoxp3+ cells in the CD4 
compartment of murine recipients at various time points post infection (D). Summary of frequency of 
TbethiFoxp3+ T cells at various time points (E). The frequency of Foxp3 expression in TbethiFoxp3- cell 
population in the absence or presence of PDL-1 after 7 days of ex vivo culture (F). Summary of Tbet+iTreg 
cell differentiation (G). CD45.2+Tbet+FoxP3- cells (0.7x106 cells) were adoptively transferred into CD45.1+ 
murine hosts that were infected with Clone-13. Cohorts were treated with either isotype control or anti-
PDL1 antibody (200g/mouse). Splenocytes were harvested at day 10 and the frequency of 
CD4+Tbet+Foxp3+ pTreg cells were evaluated (H-I). Data are shown as MeanSEM from a representative 
of one to three individual experiments involving n=3-9 mice per cohorts. Please also refer to Figure S7. 
 
Figure 7: Tbet+Th1 cells upregulate Foxp3 in tumor microenvironment 
B6.Rag2-/- mice were subcutaneously injected with B16F10 melanoma cells. At day 7 post-tumor 
inoculation, adoptive transfer of Tbet+Th1 cells was performed (A).  Mice were euthanized on day 14, 
splenocytes and TILs were isolated and then Tbet+Foxp3+ cell frequency was determined (B). Summary of 
Foxp3+Tbet+ cells from the spleen and TIL (C). Tbet+Foxp3-cells were flow sorted from the spleen and then 
expanded under iTreg conditions or iTreg conditions plus PDL-1fc. The upregulation of Foxp3 was then 
monitored by flow cytometry at day 7 post culture (D-E).  B6.Rag2-/- mice were subcutaneously injected 
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with B16F10 melanoma cells and adoptive transfer of Tbet+Th1 cells was performed at day 5. Cohorts were 
either treated with isotype control or anti-PDL1 antibody (250g/mouse) at days 5, 7 and 9. Animals were 
euthanized at day 11. Experimental methodology outlined in (F), and the frequency of Tbet+iTreg cells was 
monitored within the TILs (G-H). Experiments were performed with Tbet+Foxp3- cells transduced with 
either scramble shRNA RV or AEP shRNA RV and then treated with anti-PDL1 antibody. Frequency of 
Tbet+iTreg cells within the TILs in the different cohorts (I-J). Murine CD45.1+ hosts were reconstituted 
with B16F10 melanoma tumors and sorted CD45.2+Tbet+Foxp3- cells. Cohorts were treated with either 
isotype or anti-PDL1 antibody. Frequency of Tbet+iTreg cells was measured within the TILs (K-L). 
Experiments were repeated at least twice and data are shown as MeanSEM from one to two individual 
experiments involving n=3-8 mice per group.  
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STAR Methods 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed and will be fulfilled by the 
Lead contact, Dr. Shoba Amarnath. 
 
Experimental Model and Subject Details 
Mice 
Female C57BL/6 (B6, H-2Kb) and Balb/c (H-2Kd) mice 8- to 10- weeks old were obtained from Frederick 
Cancer Research Facility, USA or Charles River, UK. Female C57BL/6 Rag2-/- and C57BL/6 Foxp3RFP 
mice were purchased from Jackson Laboratories, Aep-/- and WT littermate controls was kindly provided by 
C. Watts. B6.Tbx21Zsgreen mice were bred with B6.Foxp3RFP mice in a specific pathogen-free facility at 
the National Institutes of Health, USA and at Newcastle University, UK. B6.Tbx21ZsGreenFoxp3RFP mice 
were utilized for all T cell lineage-tracing experiments. The use of animals for this research was approved 
by the Animal Care and Use Committee, National Cancer Institute, and National Institute of Allergy and 
Infectious Diseases,  NIH, and carried out in accordance with the NIH animal health and safety guidelines. 
Animal experiments conducted at Newcastle University were approved by the Newcastle Ethical Review 
committee and performed under a UK home office approved project license. Experimental methodology 
was in accordance to the NC3R recommendations and data are shown in accordance with ARRIVE 
guidelines. 
 
Method Details 
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Cell sorting and Flow cytometry and tetramer staining 
Unless stated otherwise, ZsGreen fluorescence was used to determine Tbet expression and RFP 
fluorescence was used to flow sort various cell populations. CD4+Tbet+Foxp3-Th cells were characterized 
by multi-parameter flow cytometry for surface markers. Cytokine phenotype of day 0 cells was measured 
by stimulating cells with phorbol-12-myristate 12- acetate (PMA) and ionomycin for four hours along with 
Golgiplug and Golgistop which was added in the last 2 hrs of incubation. Flow cytometry staining 
antibodies for CD4 (clone: RM4-4), CXCR3 (clone: CXCR3-173), PD-1 (clone: 29F.1A12), PDL-1 (clone: 
10F.9G2), CD44 (clone: IM7), CD45.1 (clone: A20), CD45.2 (clone: 104), H-2Kb (AF6-88.5), CD62L 
(clone: MEL-14), CD8 (clone: 53-6.7), CCR4 (clone: 2G12), Neuropilin-1 (clone: 3E12), Helios (clone: 
22F6), CD25 (clone: PC61) and CD127 (clone: A7R34) were purchased from BioLegend. Foxp3 (clone: 
FJK-16s), IL-10 (clone: JES5-16E3), IFN- (clone: XMG1.2) and Ki67 (clone: SolA15) were from Thermo 
Fisher Scientific. For MHC class I tetramer staining, H-2Db GP33-41 was used at 1:100 dilutions and 
staining was performed at 4o C for 1 hr. Data were acquired using either an LSR II or Fortessa or FACS 
CANTO and analyzed using FlowJo software version 9.6.4 or 10.0.6. 
 
In vitro cell culture 
CD4+Tbet+Foxp3- T helper cells were flow sorted and stimulated in 24 well cell culture plates coated with 
Anti-CD3 (clone:145-2C11; 5µg/ml) for 3 days in cell culture media [RPMI, supplemented with 10% FCS, 
glutamine (2mM), non-essential amino acids (0.1mM), 2-mercaptoethanol (50M), sodium pyruvate 
(1mM), penicillin and streptomycin (100U/ml)] along with soluble anti-CD28 (clone:37.51;2µg/ml), rmIL-
2 (80ng/ml), rhTGF-1 (2ng/ml), anti-IL-4 (BioLegend, clone:11B11;20µg/ml) and anti-IFN- 
(BioLegend, clone:XMG1.2; 20µg/ml) with or without coated PDL-1fc chimera (5g/ml). After 3 days of 
culture, cells were expanded for an additional four days in the presence of IL-2 (80ng/ml) and TGF-1 
(2ng/ml) or with IL-2 alone. Cells were then characterized by intracellular flow cytometry for Foxp3 
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expression. Both populations were flow sorted for Foxp3+ cells and are denoted as Tbet+iTreg and 
Tbet+iTregPDL1 cells. Post-differentiation Tbet+iTreg and Tbet+iTregPDL1 cells were stimulated overnight 
with Anti-CD3 and Anti-CD28 and then supernatants were subjected to a multiplex bead array luminex 
assay. Control populations of iTregs (iTreg and iTregPDL1) were generated from CD4+Tbet-Foxp3- subsets, 
which were similarly cultured and characterized. Subsequently, expanded Foxp3+ cells from the various 
subsets were sorted and utilized in in vitro suppression assays and in vivo animal models of autoimmunity 
and alloimmunity. In certain experiments, CD4+Tbet+Foxp3- T helper cells were either cultured with AEP 
inhibitor MV026630 (100M) or AEP ShRNA or Vehicle (DMSO) from day 0 of culture in addition to 
CD3, CD28, rh-IL-2 and rh-TGF-prior to being used as cellular therapeutics.  
 
In vitro Treg suppression assay 
CD4+CD25- cells were isolated using the Miltenyi Biotec Treg isolation kit and utilized in a Treg 
suppression assay as previously described (Thornton and Shevach, 1998). Purified CD4+CD25- cells 
(5x104) were labeled with CellTrace Violet and then cultured in 96 well round bottom plates in 200l 
complete media along with 2x105 irradiated T cell-depleted spleen cells (3000 cGy) as accessory cells. Anti-
CD3 (0.5g/ml) was added along with cultured flow sorted Foxp3+iTreg populations (iTreg, iTregPDL1, 
Tbet+ iTreg and Tbet+ iTregPDL1 cells) at the indicated ratios. Cells were incubated at 37o C for 72 hrs and 
proliferation and suppression was monitored by flow cytometry. Proliferation of responder T cells was 
evaluated by CellTrace Violet dilution. Percent suppression of CD4 responder T cell was calculated with 
values representing the ratio of total divided peaks to both divided and non-divided peaks, normalized to 
the anti-CD3 alone experimental group. 
 
In vivo animal models 
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Experimental Autoimmune Colitis 
B6.Rag2-/- female mice were reconstituted with B6. CD45.1+CD4+CD25-CD45RBhi (T effectors) 
populations (4x105) as previously described (Asseman et al., 1999) along with flow sorted 
B6.CD45.2+iTreg cells (1x105), iTregPDL1 cells (1x105), Tbet+iTreg (1x105), or Tbet+ iTregPDL1 cells (1x105). 
Mice were weighed weekly and loss of body weight was used as an indicator of colitis. Immune endpoints 
were measured in the splenocytes and in LPL. LPL were isolated as previously described (Asseman et al., 
1999). Briefly, large intestine was digested using Liberase TL and DNAse I followed by percoll gradient 
centrifugation. LPLs were washed twice with complete media and then used for immunological assays. 
Both splenocytes and LPL were stimulated with PMA and ionomycin along with GolgiPlug and Golgistop 
for 4 hrs and then effector cytokines were measured by intracellular flow cytometry. 
 
Experimental Allogeneic GVHD 
BM was flushed from B6 donor femurs and tibias and T cell depleted (TDBM) using CD90.2 MACS beads 
(Miltenyi Biotec). Host allogeneic (BALB/c) female mice were conditioned with total body irradiation of 
950 cGy in two divided doses three hours apart before being rescued with 107 TDBM cells together with 
1x106 CD4+CD25-T cells from WT CD45.1+ B6 donors. In addition, various flow sorted iTreg populations 
(CD45.2+; 1x106) were adoptively transferred for prevention of GVHD. Survival was monitored as a 
measure of Treg cell potency. Alloreactive IFN- was measured as follows: Single cell suspension of 
splenocytes (1x106) was cultured overnight with either syngeneic or allogeneic bone marrow derived 
dendritic cells DCs  (1x 105). Supernatant was harvested at 24 hrs and Th1 cytokines were measured by 
using a multiplex luminex bead array system. Allogenic IFN- cytokine in the supernatant was measured 
by subtracting the amount of IFN- present in the syngeneic controls.  
 
LCMV 
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Six to eight weeks old B6.Tbx21ZsGreenFoxp3RFP mice were infected with Armstrong (2x105 PFU, i.p) 
or Clone-13 virus (2x106 PFU, i.v) as previously described (Wherry et al., 2003). Titers of virus were 
determined by plaque assay on Vero cells as previously described (Ahmed et al., 1984). At indicated time 
points, spleens were harvested and the frequency of Tbet+Foxp3+ T cells was characterized by flow 
cytometry. In certain experiments, primed CD4+Tbet+Foxp3- T cells were flow sorted on day 14 post-
infection and then differentiated under iTreg conditions with or without PDL-1 followed by Foxp3 
characterization using flow cytometry. B6.CD45.1+ murine recipients were injected with anti-CD4 
(500g/mouse; day -7) infected with Clone-13 virus along with adoptive transfer of CD45.2+Tbet+Foxp3- 
cells (0.7x106). Cohorts were treated with either isotype or anti-PDL1 antibody (200g/mouse) at day 1, 5 
and 9. On day 10 Tbet+Foxp3+ cells were analyzed in spleens of the infected mice. 
 
B16F10 melanoma 
B6.Rag2-/-mice, WT mice, CD45.1 and Aep-/- mice were reconstituted with 3x105 B16F10 melanoma cells 
(kindly provided by Dr. Pawel Muranski and Prof. Nick Restifo, NCI,NIH) and the tumor was allowed to 
progress for 7 days. At day 7, murine recipients were reconstituted with 2x105 Tbet+Foxp3-T effectors from 
B6.Tbx21ZsGreenFoxp3RFP mice. At day 14 post-tumor inoculation, mice were euthanized, spleen and 
TILs were isolated and analyzed for the presence of TbethiFoxp3+ cells. In certain experiments, cohorts 
were treated with either isotype or anti-PDL1 antibody (250g/mouse) at days 5, 7 and 9. For shRNA 
experiments, Rag2-/- mice were reconstituted with tumor at day 0 along with flow sorted CD4+Tbet+Foxp3- 
T cells transduced with either scramble or AEP shRNA. Murine recipients were then treated with anti-
PDL1 antibody at days 5, 7 and 9. Host CD45.1+ murine hosts were reconstituted with tumor at day 0 along 
with flow sorted CD4+Tbet+Foxp3- T cells and then treated with antibodies at days 5, 7 and 9. Splenocytes 
and tumors were harvested at day 11 and the frequencies of Foxp3+ cells were evaluated. 
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Histological Analysis 
Representative samples of liver, intestine and colon were obtained from the mice that underwent GvHD 
and fixed in 10% phosphate buffered formalin. Samples were embedded in paraffin, sectioned and stained 
with hematoxylin and eosin. All slides were coded and read by an external pathologist (Dr. Michael 
Eckhaus) in a blinded fashion. A four-point scale of GvHD severity was used to score the samples. 
 
Affymetrix Gene Expression Profiling 
Total RNA was isolated with RNAeasy kit from Qiagen. RNA quality was checked on Agilent Bioanalyzer.  
All samples used for microarray analysis had high quality score (RIN >9).  100 ng of RNA was reverse 
transcribed and amplified using Ambion WT expression kit following manufacturer’s suggested protocol.  
Sense strand cDNA was fragmented and labeled using Affymetrix WT terminal labeling kit.  Four replicates 
of each group were hybridized to Affymetrix mouse Gene ST 2.0 GeneChip in Affymetrix hybridization 
oven at 45º C, 60RPM for 16 hrs.  Wash and stain were performed on Affymetrix Fluidics Station 450 and 
scanned on Affymetrix GeneChip scanner 3000. Data were collected using Affymetrix AGCC software. 
Statistical and clustering analysis was performed with Partek Genomics Suite software using RMA 
normalization algorithm.  Differentially expressed genes were identified with ANOVA analysis.  Genes 
that are up- or down-regulated more than 2 fold and with a p<0.001 were considered significant. 
 
Immuno Blotting 
Protein lysates were obtained from Tbet+ iTreg, and Tbet+ iTregPDL1 cells. Lysates were run on 10-20% 
SDS-PAGE gels and transferred onto nitrocellulose membrane. Membranes were blocked with 5% milk in 
TBST buffer (20mmol/L TrisHCl, 500 mmol/L NaCl, and 0.01% Tweeen-20) and incubated overnight at 
4º C with primary antibodies (Ab) in TBST containing either 5% milk or BSA. Immune reactivity was 
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detected by sequential incubation with HRP-conjugated secondary Ab and enzymatic chemiluminescence 
(Cell Signaling Technology). Primary Abs to mouse PTEN, mTOR, phospho-mTOR, Akt, phospho-AKT 
(Ser473 and Thr 308), Foxp3, P70S6K, phospho-p70S6K, ERK, phospho-ERK, GAPDH, -tubulin, -
actin were procured from Cell Signaling. AEP (Legumain) was obtained from R&D systems. Images were 
acquired using a LiCOR FcOdyssey system or Wes Simple Protein system.  
 
AEP enzyme activity 
AEP activity in cell lysates was measured in triplicates by cleavage of the substrate z-Ala-Ala-Asn-AMC 
(Bachem) as previously described (Haugen et al., 2013; Johansen et al., 1999). Briefly, cell lysate (20l) 
was added to black 96-well microplates. After the addition of 100l buffer and 50l substrate solution (final 
concentration is 10M) at pH5.8, a kinetic measurement based on increase in fluorescence over 10min was 
performed at 30o C in a plate reader and presented as enzyme units where one unit of activity was defined 
as the amount of enzyme releasing 1.0mol of product/min under the standard conditions described. 
Enzyme activity was then normalized to the enzyme activity of DCs. DC enzyme activity was set to 100% 
and then the % enzyme activity of Tbet+ iTreg and Tbet+ iTregPDL1 cells was calculated. Enzyme activity 
was also measured by using imaging flow cytometry using the AEP probe LE28 (Edgington et al., 2013). 
LE28 specifically binds to active AEP enzyme. Briefly, Tbet+ iTreg and Tbet+ iTregPDL1 cells were incubated 
with the AEP probe LE28 cy5 for 1 hr at 37º C, washed and then AEP activity was measured using flow 
cytometry. 
 
Foxp3 co-localization Assays 
The co-localization of Foxp3 in the nucleus was measured using imaging flow cytometry on the Amnis 
Image stream MKII. For this, cells were fixed and then stained with DAPI, Foxp3APC and LAMP-1 APC-
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cy7 (BioLegend, clone 1D4B). For co-localization experiments with AEP cells were stained with DAPI, 
Foxp3PE, LAMP-1 APC-Cy7, and LE28 cy5. 
Amnis Imaging Flow cytometry 
Sample Acquisition: Samples were run on an Image StreamX MKII using INSPIRE data acquisition 
software (Amnis EMD-Millipore) at a concentration of approximately 1x106 cells in 50l of PBS. The 
system was outfitted with 2 cameras, 12 channels, 405, 488, 561, 642, and 785nm lasers, and an extended 
depth of field element (EDF).  Brightfield was collected in channels 1 and 9, SSC was collected in channel 
6 at a 785nm power of 2mW, DAPI was detected in channel 7 (430-505nm filter) at a 405nm laser power 
of 10mW, TbetZsgreen was detected in channel 2 (480-560nm filter) at a 488 laser power of 20mW, Foxp3 
PE was detected in channel 3 (560-595 filter) at a 561nm laser power of 200mW, and LE28 Cy5 were 
detected in channel 11 (660-745nm filter) and LAMP1 APC-Cy7 was detected in channel 12 (745-800nm 
filter) respectively, at a 642nm laser power of 150mW.  Acquisition gates in INSPIRE were set as follows: 
a single cell gate was set on a Brightfield Area versus Brightfield Aspect Ratio plot to encompass single 
cells and eliminate debris and aggregates, a Brightfield Gradient RMS plot was used to gate single cells 
which were in focus, and gates were set in Raw Max Pixel plots to eliminate events saturating the camera 
in each fluorescent channel used.  20,000 single, focused, non-saturating events were acquired at 60X 
magnification, using the EDF element.   
 
Data Analysis: Data analyses were performed in IDEAS 6.0software (Amnis EMD-Millipore).  A 
compensation matrix was created utilizing single color controls acquired with Brightfield and the 785 laser 
turned off, and all others laser powers set to the powers listed above.  In IDEAS, single, focused, and 
nucleated (DAPI+) cells were gated and used for downstream analysis.   
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Determination of Foxp3 in the nucleus: A series of masks was created which enabled the determination of 
the amount of Foxp3 in the nucleus.  First, a tight mask was created on the nuclear image by eroding the 
default mask in one pixel (Erode (M07, 1).  Next, a mask was created which identified Foxp3 staining 
(Intensity (M11, 11_Foxp3, 100-4095)).  Lastly, a mask was created to identify pixels which contained 
DAPI staining and Foxp3 staining by combining the aforementioned masks with an AND operator ((Erode 
(M07, 1) And Intensity(M11, 11_Foxp3, 100-4095)). The area of Foxp3 inside the nucleus was determined 
by creating an Area feature on the combined DAPI:Foxp3 mask and gating the Area plot on DAPI+Foxp3+ 
cells. 
 
Determination of Foxp3 and AEP co-localization in the nucleus: A series of masks was created which 
enabled the determination of the co-localization of Foxp3 and AEP in the nucleus. First, a mask was created 
which identified Foxp3 staining (Intensity (M03, 3_Foxp3, 300-4095).  Next, a mask was created which 
identified AEP staining (Intensity (M11, 11_Legumain/AEP, 362-4095).  The DAPI mask used is as 
described in the section above. Lastly, a mask was created to identify pixels which contained DAPI, Foxp3, 
and AEP staining by combining the aforementioned masks with an AND operator (Intensity (M03, 
3_Foxp3, 300-4095) AND (Erode (M07, 1) AND Intensity (M11, 11_Legumain). The area of the pixels 
containing DAPI, Foxp3, and AEP staining was determined by creating an Area feature on the combined 
DAPI:Foxp3:AEP mask and gating the Area plot on DAPI+Foxp3+AEP+ cells. 
 
Confocal Microscopy 
Flow sorted iTregs, iTregPDL1, Tbet+iTreg and Tbet+iTregPDL1 were first stained with AEP Cy5 followed by 
fixation and permeabilization. Cells were washed with permeabilization buffer and then stained with Foxp3 
PE and DAPI. Images were acquired on a Leica SP8 point scanning confocal microscopy with while light 
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super continuum lasers. Colocalization analysis were performed as previously described (Dunn et al., 2011). 
A comprehensive explanations of the confocal analysis is provided below: 
 
Orthogonal projection view to enhance visualization of protein spatial location: An orthogonal projection 
of the image allows identification of the spatial location of a protein within the cell. It is a three-dimensional 
view of the cell but in a two-dimensional figure. A quadrant was drawn on a particular point in the nucleus, 
if all three fluorophores are present together in this 3D view, then the analysis shows this on merging the 
three images. 
 
Deconvolution of the images to enhance signal to noise ratio in an orthogonal projection:  Deconvolving 
is a recognized image processing technique to digitally reassign out of focus light to its originating focal 
plane.  Deconvolution corrects optical aberration and provide higher resolution which enhances signal to 
noise ratio therefore minimizing false positive analysis. Combining deconvolution and orthogonal 
projection enhances understanding of the spatial location and co-localization of proteins within a cell.  
 
Particle Analysis: Particle analysis was performed with the deconvolved images as recently shown(Kwon 
et al., 2017). Using this technique, we measured the number of Foxp3 and AEP particles within the nucleus. 
We next performed a quantitative analysis of the particles and plotted the values as follows: Each data point 
depicts the number of particles within the nucleus and the y axis denotes the relative volume of Foxp3 
within the nucleus and similarly the relative volume of AEP within the nucleus. If cytosolic contamination 
occurs, it will be represented in this analysis as follows. 100% on y axis denotes that the entire particle is 
within the nucleus whereas 20% denotes a particle that does not explicitly localize in the nucleus. 
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We next quantitatively measured AEP and Foxp3 co-localization. Each data point depicts the number of 
particles within the nucleus that is colocalized and the y axis denotes the value which is the sum of the 
intensity of all voxels that colocalize with each other. 
 
Foxp3 cleavage and Mass Spectrometry 
Human Foxp3 protein and Tbet protein was purchased from Origene and then used in the cleavage assay 
in the presence of purified AEP protein (kindly provided by Dr. Colin Watts). Briefly, 1g of human AEP 
protein was incubated in 200l of activation buffer (0.1M NaCl, 0.1M NaOAc, pH 4.5) in 96 well round 
bottom plates for 30 mins at 37º C. In certain conditions, the AEP inhibitor was added (100M).  Post AEP 
activation, either Foxp3 protein (5g) or Tbet protein (5g) was added to the wells with only activation 
buffer or activation buffer plus AEP or activation buffer plus AEP plus inhibitor. The plate was then 
incubated for 2 hrs at 37ºC. Samples were then reduced with LDS sample buffer and then subjected to 
immuno blotting. Once the proteins were run on a gel, they were transferred to a membrane and blotted for 
Foxp3 and Tbet. In separate experiments, gels were stained with Coomassie blue (Gel Code Blue reagent; 
Thermo Fisher Scientific) and then bands were cut out and subjected to mass spectrometry as previously 
described (Zhang et al., 2014). Briefly, bands were dehydrated using acetonitrile followed by vacuum 
centrifugation, reduced with 10 mM dithiothreitol and alkylated with 55mM iodoacetamide.  Gel pieces 
were then washed alternately with 25 mM ammonium bicarbonate followed by acetonitrile. Samples were 
digested with trypsin overnight at 37C. Digested samples were analyzed by LC-MS/MS using an 
UltiMate® 3000 Rapid Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to an Orbitrap 
Elite (Thermo Fisher Scientific, Waltham, MA) mass spectrometer. Peptide mixtures were separated using 
a gradient from 92% A (0.1% FA in water) and 8% B (0.1% FA in acetonitrile) to 33% B, in 44 min at 300 
nL min-1, using a 75 mm x 250 μm i.d. 1.7 mM CSH C18, analytical column (Waters). Peptides were 
selected for fragmentation automatically by data dependent analysis. Data produced were searched using 
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Mascot (Matrix Science UK), against the SWISSPROT database. Data were validated using Scaffold 
(Proteome Software, Portland, OR).  Additional Foxp3 degradation experiments were performed with WT 
or mutated Foxp3 expressing 293 cells. The WT Foxp3 cDNA was isolated from a BamH1 + Xho1 digest 
of plasmid purchased from Addgene.  The Mu Foxp3 containing alanine substituted for arginine was 
synthesized by Integrated DNA Technologies custom gene synthesis service.  The construct contained 
BamH1 and Xho1. These sites were used to clone both WT and mutant Foxp3 cDNAs into pCDNA3.1 and 
pEV Thy1.1 RV.  The mutant Foxp3 construct also included a Not1 site to identify recombinant 
plasmids.  The Foxp3 mutant cDNA was fully sequenced prior to use in experiments. 
 
Pulse Chase Assays for Foxp3 protein turnover 
Tbet+iTreg and Tbet+ iTregPDL1 cells were washed and then aliquoted into 24 well tissue culture plates at 
3x106/ml. In certain experiments, WT or Aep-/- iTregs were  plated into 24 well plates at 1x106/ml. Cells 
were treated with cycloheximide (150g) for the indicated time points and lysates were used to measure 
Foxp3 and Tbet protein degradation by immuno blotting. In order to block proteosomal degradation of 
Foxp3 and Tbet, MG132 (0.5 M, Sigma-Aldrich) was added to certain culture conditions. AEP inhibitor 
MV026630 (100 M, kindly provided by Prof. Colin Watts and Dr. Sanders van Kasteren) was added to 
cultures to block specific AEP mediated degradation of Foxp3. 
 
AEP and Foxp3 silencing and mutation assays 
AEP specific shRNAs were obtained from Origene. On confirming efficient silencing of AEP in NIH3T3 
cells, the most efficient shRNA was chosen for further analysis. Single-stranded oligonucleotides 
containing shRNA targeted to AEP or scrambled sequence, 20 bp complementary to the sequence flanking 
a Xho1 site within with the expression vector pEV Thy1.1 RV (gift from Dr. Vanja Lazarevic, NCI, NIH), 
and a Not1 site were purchased from IDT and annealed in buffer containing 1mM Tris pH 8.0, 50 mM NaCl 
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and 1mM EDTA. The vector pEV Thy1.1 RV was digested with Xho1.  The vector and the double stranded 
oligos were combined and a Gibson reaction (New England Biolabs) was performed.  Recombinant clones 
were identified by Not1 restriction analysis.  The integrity of the insert sequence and orientation was 
confirmed by DNA sequencing. Silencing of AEP was further confirmed in 3T3 cells and then was used to 
silencing AEP in primary murine Tbet+iTreg cells. pENTR Foxp3 was a gift from Prof. Anjana Rao 
[Addgene plasmid # 16363 (Wu et al., 2006)] containing WT human Foxp3 cDNA that was cloned into 
pEV-Thy1.1-RV using BglII and Xho1.  The AEP resistant human Foxp3 was synthesized as a mini-gene 
(IDT) and cloned into the BglII and Xho1 sites of pEV-Thy1.1-RV.  The N154A human Foxp3 mutant was 
created by inserting a 240 bp G-Block DNA fragment (IDT) between the Bcl1 and BstB1 sites using the 
Gibson reaction (New England Biolabs). AEP cDNA was obtained from Prof. Colin Watts and cloned into 
pEV-Thy1.1-RV using Xho1. For NLS experiments AEP NLS site was mutated whereby KRK was 
replaced to AAA at site 318-320. pMIGR-mFoxp3 was a gift from Prof. Dan Littman (Addgene plasmid # 
24067, unpublished).  The N153A mutant was created by inserting a 182 bp G-Block DNA fragment (IDT) 
between the Bcl1 and BamH1 sites using the Gibson reaction (New England Biolabs).  All modified 
constructs were verified by sequencing before use. 
Retroviral transductions of Tbet+iTreg cells were performed as follows. Briefly, cells were stimulated for 
24 hrs and then washed once. Cells (0.5x106) were spin inoculated with 1ml of virus supernatant in the 
presence of polybrene (4g/ml) consisting of scramble or AEP shRNA for 50 mins at 3000RPM. The cells 
were then placed at 37o C for 2 hrs after which an additional 2ml of complete RPMI media was added. 
Infection was monitored after 4 days as the percent of CD90.1 and AEP cy5 expression by flow cytometry. 
CD90.1+Foxp3+Tbet+ iTreg cells were flow sorted and then adoptively transferred in to a murine model of 
allogeneic GVHD and in vivo stability of Foxp3 in Tbet+ iTreg cells was monitored. 
 
Statistical analysis 
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Statistical analysis was determined using GraphPad Prism 7 software. For experiments where two groups 
were compared, a two-tailed student t test was performed. For comparison of three or more groups, a one-
way ANOVA was performed followed by appropriate multiple comparison tests. For survival curve 
analysis, Kaplan-Meier survival curve analysis followed by a log rank test was performed. Unless stated 
otherwise, histogram columns represent the mean values for each experiment and error bars indicate the 
standard error of the mean. Data presented were considered significant if p value was  0.05.  
 
Data and Software Availability 
The microarray data reported in this paper have been deposited in the NCBI Gene Expression Omnibus 
(GEO) database under accession number GEO:GSE113815. 
 







Supplementary Figure 1 (related to Figure 1) 
 
In vitro function of Tbet+ iTreg cells and Tbet+ iTregPDL1 cells  
Characterization of flow sorted CD4+Tbet+Foxp3- cells was performed prior to cell culture. Sorted 
cells had Th1 cell phenotype and expressed CXCR3, CD44 and PD-1 (A). Flow sorted cells also 
expressed Th1 cytokines IFN-g and IL-10, which was measured by intracellular flow cytometry (B). 
Tbet+ iTreg cells and Tbet+ iTregPDL1 cells were generated from the flow sorted Tbet+Foxp3- cells and 
then utilized in an in vitro suppression assay. Responders were labeled with CellTrace Violet 
followed by stimulation with irradiated splenocytes and anti-CD3 and proliferation was measured by 
flow cytometry (C). Various Treg cell populations were added at different ratios and proliferation 
was measured (D). Summary data for three experiments was shown (E). Cytokine profile was 
obtained using Luminex from Tbet+iTreg cells and Tbet+iTregPDL1cells from at least 6 experiments 
(F). Experiments were repeated at least 5 times and each experiment was performed with n=3-5 mice 
and are presented as Mean±SEM. 
 
  
Supplementary Figure 2 (related to Figure 2) 
 
 
Tbet+ iTregPDL1 cells have regulatory function in vivo 
Tbet+iTreg cells and Tbet+iTregPDL1 cells were generated and then utilized for the prevention of 
autoimmune colitis and alloimmune GvHD. B6.Rag2-/- mice were reconstituted with 4x105 
CD45.1+CD4+CD45RBhiCD25- T cells alone (T effectors) or along with CD45.2+ iTreg cells, 
iTregPDL1 cells, Tbet+ iTreg cells and Tbet+ iTregPDL1 cells (1x105 cells/mouse).  Weight loss was 
monitored in various cohorts (A). LPL were harvested for measuring immunological endpoints. 
Summary of T cell effector cytokine IFN-γ in various different cohorts was shown (B). Summary of 
Foxp3 (CD45.2+) expression in iTreg cells, iTregPDL1 cells, Tbet+ iTreg cells and Tbet+ iTregPDL1 cells 
in LPL (C). Function of Tbet+iTreg cells and Tbet+ iTregPDL1 cells were assessed in an experimental 
model of GvHD. Host Balb/c mice were subjected to lethal total body irradiation (950cGy) and then 
reconstituted with B6 T depleted bone marrow (BM) cells alone. All cohorts received CD4+CD25- T 
cells in addition to BM. Certain cohorts received additional cell populations as indicated. Weight loss 
of mice that succumbed to GvHD over a period of 30 days in the various different cohorts (D). 
Histology of mice that received either Tbet+ iTreg cells and Tbet+ iTregPDL1 cells was evaluated (E). 
For weight loss, each cohort consisted of n=10 mice. For histological, n=5 mice per cohorts were 
used. Cumulative data from 2 independent experiments are presented as Mean±SEM. 
  
Supplementary Figure 3 (related to Figure 3) 
 
 
PD-1 signaling downregulates AEP on Tbet+ iTregPDL1  cells and  iTregPDL1 cells 
Tbet+iTreg cells and Tbet+ iTregPDL1 cell lysates were subjected to immuno blotting analysis to 
measure AKT and mTOR signaling pathway proteins (A). Volcano plot showing log2 fold change 
versus p value in gene expression between Tbet+iTreg cells and Tbet+iTregPDL1 cells (B). Expression 
of active AEP in Tbet+iTreg cells and Tbet+ iTregPDL1 cells was measured by flow cytometry using 
the LE28 AEP Cy5 probe (C). AEP enzyme activity in Tbet+iTreg cells and Tbet+iTregPDL1 cells (D). 
Summary plot showing AEP nuclear activity in Tbet+iTreg cells and Tbet+iTregPDL1 cells (E). Naïve 
CD4+CD25- T cells and CD4+CD25+ T cells were isolated from WT mice and lysates were tested for 
AEP by immuno blotting (F). Splenocytes were harvested from WT and Pd1-/- mice, and then naïve 
cells were isolated, differentiated under iTreg conditions alone or in the presence of PDL-1 fc. AEP 
expression was analyzed in in vitro induced WT and Pd1-/- iTreg cells (G). Summary plot showing 
AEP nuclear co-expression with Foxp3 in Tbet+iTreg cells and Tbet+iTregPDL1 cells (H). Orthogonal 
projection view on confocal imaging data is shown in iTreg cells (I). The nucleus stained with DAPI 
and is depicted as blue, active AEP stained with activity probe AEP Cy5 is depicted as red and Foxp3 
stained with Foxp3 PE is depicted as green. A quadrant is drawn on a particular point in the nucleus 
(blue image; top left panel) and then pasted on to AEP (top right panel) and Foxp3 staining (bottom 
left panel). If all three fluorophores are present together in this 3D view, then the analysis shows this 
on merging the three images (denoted as yellow in bottom right panel). The yellow is surrounded by 
blue in the x, y and z axis further suggesting the presence of active AEP and Foxp3 within the nucleus. 
Orthogonal projection view on deconvolved images (J). Deconvolution will correct optical aberration 
and provide higher resolution which enhances signal to noise ratio therefore minimizing false positive 
analysis. Combining deconvolution and orthogonal projection enhances our understanding of the 
spatial location and co-localization of proteins within a cell. Images processed by orthogonal 
projection and deconvolving is depicted on the top and bottom panels (K). Particle analysis of 
Foxp3(L; top panels) and AEP (L; bottom panels) within the nucleus (L; left panels showing image 
of the cell at normal view and right panels at 600) and quantitative analysis (M) is shown. Similarly, 
colocalization of AEP and Foxp3 within the nucleus is depicted (N; left panel and 600 view right 
panel) and quantitative analysis (O) is shown. Experiments were repeated 3 times and representative 
immuno blots are shown. Cumulative data are shown as Mean±SEM. 
  
Supplementary Figure 4 (related to Figure 3) 
 
AEP inhibition prevents Foxp3 protein turnover in Tbet+iTreg cells and iTreg cells 
Protein turnover was measured using standardized cycloheximide assays. Tbet+iTreg cells and Tbet+ 
iTregPDL1 cells were tested for the rate of Foxp3 turnover. Tbet+ iTreg cells and Tbet+ iTregPDL1 cells 
were differentiated and then treated with cycloheximide (150µg/ml) at different time points. Certain 
conditions were supplemented with AEP inhibitor (AEPi; MV026630; 100 µM), or leupeptin (1mM) 
or MG132 (0.5µM). Cell lysates were then subjected to immunoblotting (top panel). Foxp3 was 
normalized to the internal control GAPDH, and time 0hr was set as 100% then percent Foxp3 
degraded is shown (bottom panel). Data is shown from 5 independent experiments (A). WT and Aep-
/- CD4+CD25- T cells were differentiated under iTreg conditions and then Foxp3 turnover was 
measured in the presence of cycloheximide (B). Map showing AEP specific sites within the Foxp3 
protein. The symbol N denotes Asparagine and A denotes alanine. Human mutant 1 was mutated at 
all N sites with A; human mutant 2 was mutated at N154 to alanine. Mouse mutant 1 was mutated at 
N153 to alanine (C). Plasmid map and the cloning sites of the various WT and mutant Foxp3, AEP 
shRNA, human AEP protein and mutant AEP protein were shown (D). Immuno blot of HEK293T 
cells transduced with human WT and mutant 1 human Foxp3. Cell lysates were subjected to AEP 
degradation assay and then WT and mutant human Foxp3 was determined (E). Relative amounts of 
WT versus mutant Foxp3 protein normalized to 0 hr WT and 0 hr mutant were shown (F). 
Experiments were repeated 3 times and data shown are from one independent experiment. Summary 
plots are depicted as Mean±SEM. 
 
  
Supplementary Figure 5 (related to Figure 4) 
 
 
AEP specific Foxp3 mutation or AEP downregulation or AEP NLS mutation regulates Foxp3 
protein stability.  
CD4+CD25- T cells from WT mice were activated with anti-CD3, anti-CD28 and IL-2 for 24 hrs and 
then transduced with human WT or mutant 2 human Foxp3 or mouse WT or mutant 1 mFoxp3. At 
day 4, cells were stained with DAPI and either human or mouse Foxp3 and then subjected to confocal 
microscopy (A). The ability of Foxp3 transduced cells to produce IFN-g was tested by stimulating 
the cells with PMA plus ionomycin for 4 hrs and golgistop and golgiplug were included during the 
last 2hrs of stimulation. Cells were then subjected to intracellular flow cytometry (B). CD4+CD25- 
cells were isolated from WT and Aep-/- mice and then differentiated in the presence of anti-CD3, anti-
CD28, IL-2 and TGF-b1 in the absence or presence of AEP inhibitor for 3 days followed by expansion 
in IL-2 alone for another four days. At day 7, Foxp3 expression was measured by intracellular flow 
cytometry (C). Summary of Foxp3 expression in the various cohorts was shown (D). Tbet+iTregPDL1 
cells were activated with anti-CD3, anti-CD28, IL-2 and TGF-b1 for 24 hrs and then transduced with 
human AEP RV. At day 4, cell lysates were measured for human AEP protein expression (E). 
Transduced cells were stained with DAPI and AEP LE28 Cy5 probe and then subjected to confocal 
microscopy (F). Aep-/- iTreg cells were transduced with empty vector or AEP over-expressing RV 
and then Foxp3 stability was tested at day 7 post expansion (G). Tbet+iTreg cells from WT mice were 
activated with anti-CD3, anti-CD28, IL-2 and TGF-b1 for 24 hrs and then transduced with mouse 
control (scramble) shRNA or AEP shRNA. At day 4, AEP expression was measured by immunoblot 
analysis (H), expression of Thy1.1 in the transduced cells (I), and active AEP was measured by flow 
cytometry (J). AEP was mutated at the nuclear localization sequence and then cloned into a Thy1.1 
vector. CD4+CD25- T cells were isolated from Aep-/- mice and then stimulated under iTreg conditions. 
During the stimulation, cells were infected with retrovirus containing either empty vector (EV), AEP 
overexpressing vector (AEP RV) or AEP NLSmu (KRK-AAA mutation, site 318-320). Successful 
infection was measured by flow cytometry in the various cohorts using the AEP Cy5 probe (K). At 
day 7, Foxp3 expression was measured by flow cytometry in the listed cohorts (L-M).  Experiments 
were repeated three times and data shown are Mean±SEM. 
 
  
Supplementary Figure 6 (related to Figure 5) 
 
AEP deficiency delays loss of Foxp3 in vivo 
Splenocytes were harvested from WT and Aep-/- mice, and then CD4+Foxp3+ T cells were 
characterized for Treg markers namely CD25, CD127, Neuropilin-1 and Helios (A-B). Splenocytes 
were stimulated for 4 hrs in the presence of PMA plus ionomycin and then treated with golgiplug and 
golgistop for the last 2 hrs of stimulation. Cells were then stained for Th1 cell, Th2 cell, Th17 cell 
specific cytokines and subjected to intracellular cytometry (C). Naïve T  cells from WT and Aep-/- 
mice were isolated, differentiated under iTreg conditions for 3 days. Foxp3 expression was analyzed 
in in vitro induced WT and Aep-/- Treg cells (D). Balb/c mice were subjected to total body irradiation, 
followed by reconstitution with CD45.1+ bone marrow cells plus CD45.1+CD4+CD25- T cells. 
Certain cohorts received CD45.2+ WT or Aep-/- iTreg cells in addition to bone marrow cells and 
CD45.1+CD4+CD25- T cells. Foxp3 expression within the WT and Aep-/- iTreg cells at day 14 post-
transplant (E). Frequency of CD45.2+Foxp3+ cells in the spleen and lymph nodes of the various 
cohorts (F). Experiments were repeated twice and each cohort had n=4-5 mice. Data are shown as 
Mean±SEM.  
  
Supplementary Figure 7 (related to Figure 6) 
 
Tbethi cells express PD-1 during acute and chronic LCMV infection 
B6.Tbx21ZsgreenFoxp3RFP mice were infected with LCMV Armstrong (2x105 PFU) and then 
monitored for CD4+TbethiFoxP3+ cells and CD4+TbethiPD-1+ cell kinetics. Absolute numbers of 
CD4+TbethiFoxP3+ cells (A), frequency of PD-1 expressing cells at different time points (B), and 
absolute numbers of PD-1 expressing cells at different time points were shown (C). 
B6.Tbx21ZsgreenFoxp3RFP mice were infected with LCMV Clone-13 (2x106 PFU) and then 
monitored for CD4+TbethiFoxP3+ cells and CD4+TbethiPD-1+ cells kinetics. Absolute numbers of 
CD4+TbethiFoxP3+ cells (D), frequency of PD-1 expressing cells at different time points (E), and 
absolute numbers of PD-1 expressing cells at different time points were shown (F). CD45.1+ hosts 
were infected with Clone 13 and reconstituted with CD45.2+CD4+Tbet+FoxP3- cells. Cohorts were 
treated with isotype or anti-PDL1 antibody (200µg/mouse). At day 10, splenocytes were harvested 
and the frequency of CD45.1+CD8+ T cells (G, left two top panels; H), that were Ki67+ (G, left two 
bottom panels; I) were determined. The frequency of CD8+CD44+ cells (G, top middle panels; J), 
that were Ki67+ cells (G, bottom middle panels; K) is shown. The frequency of GP33 specific CD8+ 
T cells (G, top right two panels; L), and that were Ki67+ (G, bottom right two panels; M) were 
measured. Experiments were repeated twice and each cohort had n=3-8 mice. Representative data 
from one experiment is shown as Mean±SEM. 	 	
Supplementary Table 1: AEP-specific semi-tryptic cleavage  in Foxp3 bands 2 and band 3 
(related to Figure 3) 	Sequence-Band 2- AEP cleavage site  Start  Stop 
(R)PGKPSAPSLALGPSPGASPSWR(A) 6 27 
(K)ASDLLGAR(G) 32 39 
(N)VASLEWVSR(E) 155 163 
(R)KDSTLSAVPQSSYPLLANGVcK(W) 179 200 
(K)VFEEPEDFLK(H) 207 216 
(R)EmVQSLEQQLVLEK(E) 237 250 
(R)EMVQSLEQQLVLEK(E) 237 250 
(R)EmVQSLEQQLVLEK(E) 237 250 
(L)SAmQAHLAGK(M) 254 263 
(K)GSccIVAAGSQGPVVPAWSGPR(E) 278 299 
(R)EAPDSLFAVRR(H) 300 310 
(R)WAILEAPEK(Q) 348 356 
(R)WAILEAPEKQR(T) 348 358 
(K)cFVRVESEK(G) 394 402 
(K)GAVWTVDELEFRK(K) 403 415 
Sequence-Band 3- Additional degraded band   
(R)PGKPSAPSLALGPSPGASPSWR(A) 6 27 
(K)ASDLLGAR(G) 32 39 
(R)GPGGTFQGR(D) 40 48 
(R)GGAHASSSSLNPmPPSQLQLPTLPLVmVAPSGAR(L) 52 85 
(R)KDSTLSAVPQSSYPLLANGVcK(W) 179 200 
(R)EmVQSLEQQLVLEK(E) 237 250 
(R)EMVQSLEQQLVLEK(E) 237 250 
(R)EmVQSLEQQLVLEK(E) 237 250 
(R)EMVQSLEQQLVLEKEK(L) 237 252 
(L)SAmQAHLAGK(M) 254 263 
(R)WAILEAPEK(Q) 348 356 
	
